ProfileGDS5678 / 1429150_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 57% 57% 57% 56% 55% 57% 57% 56% 59% 57% 58% 60% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4700956
GSM967853U87-EV human glioblastoma xenograft - Control 23.4654157
GSM967854U87-EV human glioblastoma xenograft - Control 33.453757
GSM967855U87-EV human glioblastoma xenograft - Control 43.3950557
GSM967856U87-EV human glioblastoma xenograft - Control 53.3821656
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4840955
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5518157
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4497157
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3906856
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5180559
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4476457
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.449558
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6167160
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4559657